US · Healthcare · Biotechnology
EPS came in at -0.04 against a street estimate of -0.07 — a beat of 42.9%.
Analysts rate iBio, Inc. Common Stock a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $5.69.
| Fund | Stake |
|---|---|
| Affinity Asset Advisors, LLC | 6.23% |
| Cormorant Asset Management, LLC | 5.55% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 5.47% |
| Vestal Point Capital LP | 4.04% |
| Vanguard Capital Management, LLC | 3.26% |
| Frazier Life Sciences Management, L.P. | 3.04% |
| Ensign Peak Advisors Inc | 2.85% |
| Woodline Partners LP | 2.76% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for iBio, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.